---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-029854"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T00:56:35.339173+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics sells dialysis & biopsy product portfolio to Merit Medical for $100M cash

## Summary
- Closed June 8, 2023; proceeds used to repay ~$49.8M in debt under credit agreement, terminating it.
- Estimated net cash proceeds of $46.8M after transaction costs and debt payoff.
- Sold business contributed $23.7M revenue (9mo Feb 2023) and $27.7M (FY2022); pro forma operating loss increased ~$12.7M and ~$14.9M.
- Company entered transition services and contract manufacturing agreements; five-year non-compete on sold business.
- Pro forma balance sheet shows cash rising to $76.9M and long-term debt eliminated.

## SEC filing metadata
- accession: 0001140361-23-029854
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036123029854/0001140361-23-029854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036123029854/brhc20054314_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-029854
- JSON: https://secwatch.observer/filing/0001140361-23-029854.json
- Plain text: https://secwatch.observer/filing/0001140361-23-029854.txt

## Key facts
- M&A Transactions
  ANGIODYNAMICS INC completed a disposition involving Merit Medical Systems, Inc. for $100,000,000 in cash (closed 2023-06-08).
  - Action: disposition
  - Counterparty: Merit Medical Systems, Inc.
  - Consideration: $100,000,000 in cash
  - Closing: 2023-06-08
  source text: to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy product of AngioDynamics (the “ Business ”) for a purchase price equal to $100,000,000 in cash, subject to the terms and conditions of the Asset Purchase Agreement (the “ Transaction ”). The Transaction was effective as of 12:01 a.m. mountain time on June 8, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036123029854/0001140361-23-029854-index.htm
- Material Agreements
  ANGIODYNAMICS INC entered into Asset Purchase Agreement with Merit Medical Systems, Inc. valued at $100,000,000 (effective 2023-06-08).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Merit Medical Systems, Inc.
  - Value: $100,000,000
  - Effective: 2023-06-08
  source text: On June 8, 2023, AngioDynamics, Inc., a Delaware corporation (“ AngioDynamics ” or the " Company "), entered into an asset purchase agreement (the “ Asset Purchase Agreement ”) with Merit Medical Systems, Inc., a Utah corporation (“ Merit ”), pursuant to which Merit acquired the dialysis product portfolio and BioSentry tract sealant system biopsy product of AngioDynamics (the “ Business ”) for a purchase price equal to $100,000,000 in cash, subject to the terms and conditions of the Asset Purchase Agreement (the “ Transaction ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036123029854/0001140361-23-029854-index.htm
- Material Agreements
  ANGIODYNAMICS INC terminated Credit Agreement with lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger (effective 2022-06-08).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger
  - Effective: 2022-06-08
  source text: On June 8, 2022, AngioDynamics used a portion of the consideration received in connection with the Transaction to repay all amounts owed under AngioDynamics’ existing Credit Agreement, dated as of August 30, 2022, with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and KeyBank National Association, as co-syndication agents, and JPMorgan Chase Bank N.A., as sole bookrunner and sole lead arranger (the “ Credit Agreement ”), and as a result, the Credit Agreement was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036123029854/0001140361-23-029854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.